Return on Investments: An indicator of how profitable a company is relative to its assets invested by shareholders and long-term bond holders. Calculated by dividing a company's operating earnings by its long-term debt and shareholders equity. Calculated as: Income from Continuing Operations / (Total Long-Term Debt + Shareholders Equity)
Apellis Pharmaceuticals, Inc. (APLS) had Return on Investments of -29.04% for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$781.37M |
|
$-197.88M |
|
$117.72M |
|
$663.64M |
|
$946.35M |
|
$-164.98M |
|
$-31.74M |
|
$-196.72M |
|
$-196.72M |
|
$-197.88M |
|
$-197.88M |
|
$-197.88M |
|
$-197.88M |
|
$-164.98M |
|
$-152.69M |
|
123.91M |
|
123.91M |
|
$-1.60 |
|
$-1.60 |
|
| Balance Sheet Financials | |
$788.95M |
|
$2.95M |
|
$96.10M |
|
$885.05M |
|
$185.51M |
|
$452.83M |
|
$471.00M |
|
$656.51M |
|
$228.54M |
|
$228.54M |
|
$228.54M |
|
124.50M |
|
| Cash Flow Statement Financials | |
$-87.87M |
|
$-0.40M |
|
$149.24M |
|
$352.30M |
|
$412.61M |
|
$60.31M |
|
$114.13M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.25 |
|
-- |
|
-- |
|
0.66 |
|
1.98 |
|
84.93% |
|
-21.11% |
|
-21.11% |
|
-19.54% |
|
-25.18% |
|
-25.32% |
|
$-88.27M |
|
-- |
|
-- |
|
-- |
|
0.88 |
|
1.45 |
|
2.95 |
|
123.75 |
|
-86.58% |
|
-86.58% |
|
-22.36% |
|
|
Return on Investments |
-29.04% |
$1.84 |
|
$-0.71 |
|
$-0.71 |
|